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Summary
Background The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of 
mantle cell lymphoma, but its use was restricted by high haematological toxicity. We aimed to assess the effi  cacy and 
safety of an R-BAC regimen with low-dose cytarabine (RBAC500).
Methods In this multicentre, phase 2 trial, we recruited previously untreated patients with an established histological 
diagnosis of mantle cell lymphoma from 29 Fondazione Italiana Linfomi centres in Italy. Patients had to be older than 
65 years and fi t according to the comprehensive geriatric assessment, or aged 60–65 years if they were ineligible for 
high-dose chemotherapy plus autologous stem-cell transplantation and were fi t or unfi t. All patients received 
RBAC500 (rituximab 375 mg/m² on day 1, bendamustine 70 mg/m² on days 2 and 3, and cytarabine 500 mg/m² on 
days 2–4; all administered intravenously) every 4 weeks for up to six cycles. Primary endpoints were the proportion of 
patients achieving complete response at the end of treatment and toxicity, defi ned as the occurrence of any of the stop 
treatment criteria or of any episode of relevant toxicity. All patients who started at least one cycle of RBAC500 were 
included in the primary and safety analyses. Using effi  cacy and toxicity as a composite primary endpoint, we 
considered the fi nal conclusion positive if more than 28 of 57 patients achieve complete response and fewer than 18 of 
57 patients report toxicities. This study is registered with EudraCT, number 2011-005739-23, and ClinicalTrials.gov, 
number NCT01662050, and is completed. 
Findings Between May 2, 2012, and Feb 25, 2014, we enrolled 57 patients (median age 71 years, IQR 67–75). 54 (95%) 
patients received at least four RBAC500 cycles (three discontinued because of toxicity), and 38 (67%) completed 
six cycles. Two (4%) had disease progression (one after the fourth cycle and one after the sixth cycle). All 52 (91%, 
lower limit of one-sided 95% CI 85%) remaining patients achieved complete response at the end of treatment. 
23 (40%, upper limit of one-sided 95% CI 53%) of 57 patients had at least one episode of relevant toxicity. The most 
frequent grade 3–4 haematological toxicities were neutropenia (149 [49%] of 304 cycles) and thrombocytopenia 
(158 [52%]). Most treatment-related non-haematological adverse events were of grade 1–2, with the most frequent 
ones being fatigue (14 [25%] patients), nausea or vomiting (12 [21%]), and infusion-related reactions or tumour lysis 
syndrome (12 [21%]). 41 (72%) patients required a dose reduction. 12 patients died during the study, but no deaths 
were related to treatment. 
Interpretation RBAC500 is an eff ective treatment for elderly patients with mantle cell lymphoma and, despite not 
meeting our prespecifi ed safety boundary, haematological toxicity was manageable with appropriate supportive care 
and dose reduction. Since maintenance therapy is not required, RBAC500 could be considered an option and should 
be studied in phase 3 trials. 
Funding Fondazione Italiana Linfomi and Mundipharma.
Introduction
Mantle cell lymphoma is an aggressive form of non-
Hodgkin lymphoma characterised by continuous 
relapses and no standard initial therapy.1 Eff ective, well 
tolerated, and aff ordable front-line therapeutic options 
are urgently needed.2 Traditional chemotherapy regimens 
such as R-CHOP (rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone) have been 
associated with only modest complete response 
(34–48%), with median progression-free survival of 
16·6–22·1 months.3–5 The eff ectiveness of these regimens 
can be improved either by rituximab maintenance6 or by 
the replacement of vincristine with bortezomib.7 
Additionally, bendamustine combined with rituximab 
has improved complete response and progression-free 
suvival compared with R-CHOP in two randomised 
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trials5,8 of mantle cell lymphoma and was well tolerated in 
older or frail patients. 
The incorporation of high-dose cytarabine (≥1 g/m²) 
has been widely recognised as highly benefi cial in the 
treatment of mantle cell lymphoma, primarily in intensive 
regimens for younger patients (aged <65 years).9–11  Results 
from preclinical studies12,13 have shown that bendamustine 
and cytarabine have distinct and synergistic mechanisms 
of action in mantle cell lymphoma cell lines, especially 
when administered sequentially. The R-BAC (rituximab, 
bendamustine, and intermediate-dose cytarabine 
[800 mg/m²]) regimen led to a 95% complete response in 
a preliminary pilot series of 20 previously untreated 
elderly patients (aged ≥65 years) with mantle cell 
lymphoma.14 However, this regimen was associated with 
substantial haematological toxicity, especially grade 3–4 
thrombocytopenia (70 [70%] of 100 cycles). 
In this trial, we aimed to assess whether reduction of 
cytarabine dose to 500 mg/m² in the R-BAC regimen 
could decrease haematological toxicity while preserving 
antitumour activity in elderly patients with mantle 
cell lymphoma.
Methods
Study design and participants
In this multicentre, single-group, phase 2 study, we 
recruited previously untreated patients with an 
established histological diagnosis of mantle cell 
lymphoma on lymph node biopsy, bone marrow biopsy, 
or extranodal tissue from 29 Fondazione Italiana 
Linfomi centres in Italy. Patients were older than 
65 years and fi t according to the comprehensive 
geriatric assessment, or aged 60–65 years if they were 
ineligible for high-dose chemotherapy plus autologous 
stem-cell transplantation and were fi t or unfi t according 
to the comprehensive geriatric assessment (see 
appendix p 2 for the modifi ed comprehensive geriatric 
assessment). The diagnostic criteria of mantle cell 
lymphoma included positivity for cyclin D1 and SOX11 
expression (mandatory in patients who were cyclin D1 
expression or t(11;14) negative), and expression of CD20 
and CD5. Eligible patients also had to have bi-
dimensionally measurable disease, Eastern Cooperative 
Oncology Group (ECOG) performance status 0–2, and 
adequate cardiac function, renal function (creatinine 
clearance >40 mL/min) with preserved diuresis, and 
hepatic function (alanine aminotransferase and 
aspartate aminotransferase <2·5 times the upper limit 
of normal and total bilirubin <2 mg/dL, unless directly 
attributable to the patient’s tumour). Any blood cell 
count was allowed, if it was related to bone marrow 
involvement.
Patients were excluded if they had in-situ mantle cell 
lymphoma; non-nodal leukaemic disease; active 
malignant diseases other than lymphoma; active 
hepatitis B or C; HIV positivity; medical conditions or 
organ injuries that could interfere with therapy 
administration; active bacterial, viral, or fungal infection 
requiring systemic therapy; seizure disorders requiring 
anticonvulsant therapy; severe chronic obstructive 
pulmonary disease with hypoxaemia; history of severe 
cardiac disease (New York Heart Association functional 
Research in context
Evidence before this study
To establish the best available upfront treatment for patients 
with mantle cell lymphoma who are ineligible for autologous 
stem-cell transplantation, we searched PubMed from 
Jan 1, 2010, to Sept 2, 2016, for all phase 2 and 3 trials, with 
no other inclusion criteria or restrictions, using the search 
terms “mantle cell lymphoma” and “elderly”. We identifi ed 
four large randomised studies. The fi rst two studies showed 
that the effi  cacy of R-CHOP (rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone) 
can be signifi cantly improved either by the addition of 
rituximab maintenance or by replacement of vincristine with 
bortezomib. The other two studies showed superiority of the 
bendamustine–rituximab regimen over R-CHOP-like 
treatment. Moreover, a growing amount of data indicate that 
new targeted drugs are changing the landscape of mantle cell 
lymphoma therapy, with encouraging responses when 
administered alone or in combination with chemotherapy. 
R-BAC is a regimen combining bendamustine and rituximab 
with intermediate-dose cytarabine, a drug that is considered 
the mainstay for treatment of younger patients (aged 
<65 years) with mantle cell lymphoma. In a pilot study, R-BAC 
has shown encouraging effi  cacy but substantial 
haematological toxicity.
Added value of this study
In this phase 2 study of R-BAC in the upfront treatment of 
elderly patients with mantle cell lymphoma, the dose of 
cytarabine was lowered to 500 mg/m² (RBAC500). 
Haematological toxicity was frequent but manageable with 
supportive care and dose reduction, and a high proportion of 
patients had a complete response, including durable responses 
of at least 3 years for most patients. Our results validate earlier 
fi ndings and will hopefully contribute to research progress in an 
area where eff ective regimens are urgently needed.
Implications of all the available evidence
RBAC500 is an eff acacious, tolerated regimen for elderly patients 
with mantle cell lymphoma. Its effi  cacy compares favourably with 
other regimens, with or without ritiximab maintenance, in this 
patient population. At present, expensive new drugs and 
combination regimens for mantle cell lymphoma are increasingly 
followed by prolonged maintenance. Results of this trial suggest 
that RBAC500 should be tested in phase 3 studies, and could be 
considered as an inexpensive and short-term option.
See Online for appendix
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class III–IV, myocardial infarction within 6 months, 
ventricular tachyarrhythmias, dilatative cardiomyopathy, 
or unstable angina); uncontrolled diabetes; known 
hypersensitivity or anaphylactic reactions to murine 
antibodies and proteins, bendamustine, or mannitol; 
major surgery within 4 weeks of study day 1; CNS 
involvement; or any coexisting medical or psychological 
condition that would preclude participation in the study 
or compromise the patient’s ability to give informed 
consent, or that might aff ect the interpretation of the 
results, or render the patient at high risk from treatment 
complications.
The study was done in accordance with the principles 
of the Declaration of Helsinki and Good Clinical Practice. 
Ethics approval was granted by the institutional review 
board at each participating institution, and all patients 
provided written informed consent. 
Procedures
Baseline assessment included bone marrow biopsy, 
tumour staging with contrast-enhanced CT, and PET. 
Paraffi  n blocks of the diagnostic specimen were collected 
for central pathological review and central Ki67 assess-
ment, which were done by an investigator (SAP) 
according to criteria of the WHO Classifi cation 
(2008 edition).15
All patients received RBAC500 (rituximab 375 mg/m² 
on day 1; bendamustine 70 mg/m² over 30–60 min on 
days 2 and 3; cytarabine 500 mg/m² over a 2 h infusion 
starting 2 h after bendamustine on days 2–4; all 
administered intravenously) every 4 weeks for up to 
six cycles. Prophylaxis with granulocyte colony-stimulating 
factor (10 μg/kg) was given 3 days after the last cytarabine 
dose in every cycle. Recovery of absolute neutrophil count 
to 1000 cells per μL and platelet count to 75 000 platelets 
per μL was required before starting cycles. If grade 3–4 
haematological toxicity was present on day 1 of the next 
cycle, subsequent cycles were postponed for a maximum 
of 2 weeks, and doses of bendamustine and cytarabine 
reduced by 25%. Allopurinol (100–300 mg per day) was 
used for prevention of tumour lysis syndrome for at 
least the fi rst 2 weeks of treatment. Prophylaxis with 
trimethoprim–sulfamethox azole or pentacarinat aerosol 
was mandatory in all patients. Aciclovir was mandatory 
only in patients with a previous history of viral herpetic 
reactivations. The use of steroid-containing eyedrops was 
allowed but was restricted to the days of active treatment 
with cytarabine. 
Patients who did not respond to the fi rst two cycles 
were discontinued from the study. Response assessment 
after completion of therapy included CT, PET, and bone 
marrow examination. Patients subsequently had clinical 
examination, laboratory tests (blood counts, renal and 
hepatic function exams, lactate dehydrogenase), and CT 
scan every 3 months for the fi rst year after end of 
treatment and then every 6 months for 2 more years 
(minimum 24 months of follow-up). 
Centralised assessment of minimal residual disease was 
done at the University of Torino (Torino, Italy) at diagnosis, 
before cycle 3, and at 1 month, 6 months, 12 months, and 
24 months after the end of treatment. We used allele-
specifi c oligonucleotide nested PCR to assess minimal 
residual disease in bone marrow and peripheral blood 
samples, using patient-specifi c immunoglobulin heavy-
chain variable region gene rearrangement or the BCL1 
product of the t(11;14) translocation, or both (if available), 
as previously reported.16 The sensitivity of the nested PCR 
approach was three neoplastic rearrangements in 
10⁶ normal cells (ie, 3·00 × 10–⁶) in repeated dilution 
assays.17
Outcomes
The primary effi  cacy outcome was the proportion of 
patients achieving complete response—based on results 
from CT, PET, and bone marrow biopsy and defi ned 
according to 2007 International Working Group response 
criteria—at the end of treatment.18 The primary safety 
outcome was toxicity, defi ned as the occurrence of any of 
the stop treatment criteria or of any episode of relevant 
toxicity. Stop treatment criteria included the occurrence 
of relevant toxicity for two subsequent or consecutive 
cycles, despite the 25% dose reduction, or grade 3–4 
haematological or non-haematological toxicity on day 28 
of a cycle that did not resolve within 2 weeks. Relevant 
toxicity was defi ned as grade 4 cytopenia lasting for more 
than 6 days, grade 3–4 non-haematological toxicity, or 
febrile neutropenia lasting for more than 3 consecutive 
days regardless of response to treatment.
Secondary outcomes were molecular response (ie, the 
proportion of patients with molecular rearrangements at 
baseline that became negative during treatment, 
measured by qualitative and quantitative PCR); 
progression-free survival from enrolment until disease 
progression, relapse, or death from any cause; overall 
survival from enrolment until death from any cause; 
duration of response (measured from the fi rst assessment 
that documented complete or partial response to the date 
of disease relapse or progression); the proportion of 
patients completing all six RBAC500 cycles; and the 
proportion of patients who had dose reductions or delays.
Safety was assessed by documentation of adverse events 
(according to the US National Cancer Institute Common 
Terminology Criteria version 4.0), clinical laboratory 
results, vital signs, and physical examinations.
Statistical analysis
We adopted the Bryant and Day two-stage design19 for 
sample size calculation, with a composite effi  cacy–toxicity 
primary endpoint on the basis of our previous experience 
with R-BAC.14 The Bryant and Day design assumes that 
toxicity and activity are independent; although this 
assumption might be unlikely in some trials, the design 
has proved robust to mis-specifi cation of the relation 
between toxicity and activity.20 We set the upper bounds 
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on the probabilities of erroneously recommending the 
treatment at 0·05 both when complete response was 
inadequate and when toxicity was unacceptable. The 
upper bound on the probability of failing to recommend 
the treatment when it was acceptable with respect to both 
response and toxicity was 0·2 (80% power). We fi xed the 
probability of unacceptable complete response at 
0·40 and the probability of acceptable complete response 
at 0·60. In an analogous manner, the cutoff s for 
toxicity probabilities were 0·40 (unacceptable) and 
0·20 (acceptable). According to these parameters, 
19 patients were required for the fi rst stage and 57 patients 
for the second stage. The fi nal conclusion would be 
positive if more than 28 of 57 patients achieve complete 
response and fewer than 18 of 57 patients report toxicities. 
Therefore, we aimed to recruit 57 patients.
All patients who started at least one cycle of RBAC500 
were included in the effi  cacy and safety analyses. We 
used descriptive statistics and their 95% CIs to 
summarise the effi  cacy and safety endpoints. We 
reported only one-sided CIs since the Bryant and Day 
design implies that two one-sided hypotheses are to be 
tested (ie, proportion of responses larger than the null 
hypothesis and frequency of toxicities lower than the null 
hypothesis). Time-to-event variables were analysed with 
the Kaplan-Meier method. We used StatView (Abacus 
Concepts, Berkeley, CA, USA) for statistical analyses, and 
the data cutoff  date for the fi nal analysis was Aug 15, 2016.
A data monitoring committee, composed of 
independent representatives of Fondazione Italiana 
Linfomi (pharmacovigilance offi  ce), oversaw the study. 
Pharmacovigilance and monitoring were done during 
study accrual and treatment phase. All serious adverse 
events and suspected unexpected serious adverse 
reactions were analysed in real time by an investigator 
(CV) and by an independent monitoring team of 
Fondazione Italiana Linfomi. This study was registered 
with EUDRA-CT, number 2011-005739-23, and 
ClinicalTrials.gov, number NCT01662050.
Role of the funding source
Fondazione Italiana Linfomi was involved in study design, 
data collection, data analysis, data interpretation, and 
writing of the report. Bendamustine was provided by 
Mundipharma Pharmaceuticals, which also provided a 
grant to Fondazione Italiana Linfomi to partly cover the 
management costs of this study; Mundipharma 
Pharmaceuticals had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report, and did not see the fi nal results before 
submission. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for the 
decision to submit for publication. 
 Results
Between May 2, 2012, and Feb 25, 2014, we enrolled 
57 patients from 29 centres. 49 (86%) patients had 
diagnostic biopsy samples confi rmed by central 
pathology review as mantle cell lymophoma, and the 
remaining eight (14%) patients were included after 
review of centrally submitted biopsy reports. No patient 
was excluded on the basis of central pathology review. 
Median age was 71 years (IQR 67–75, range 61–79), 
43 (75%) patients were male, and none presented with 
Data (n=57)
Median age (IQR), years 71 (67–75)
Sex
Male 43 (75%)
Female 14 (25%)
Ann Arbor stage
II 5 (9%)
III–IV 52 (91%)
Bone marrow involvement
Yes 36 (63%)
No 21 (37%)
Eastern Cooperative Oncology Group performance status
0–1 54 (95%)
2 3 (5%)
Morphological variants
Classical 43 (75%)
Pleomorphic 8 (14%)
Blastoid 6 (11%)
Ki67 index*
Median (IQR) 20% (8–33)
<30% 35/51 (69%) 
≥30% 16/51 (31%)
MIPI
Low risk 9 (16%)
Intermediate risk 23 (40%)
High risk 25 (44%)
Data are n (%) or n/N (%) unless indicated otherwise. MIPI=Mantle Cell 
Lymphoma International Prognostic Index. *Six patients had no Ki67 data since 
they did not have available material for central revision. 
Table 1: Baseline characteristics
Figure 1: Trial profi le
57 patients enrolled
57 had at least two cycles
54 had at least four cycles
3 discontinued because of
 toxicity or adverse events
38 had six cycles
16 discontinued 
       11 toxicity or adverse events
         1 disease progression
         4 doctor or patient decision
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non-nodal leukaemic disease, in agreement with our 
inclusion criteria (table 1).
304 cycles of RBAC500 were given. Of 57 eligible 
patients, 54 (95%) received at least four cycles of 
RBAC500, and 38 (67%) had six cycles (fi gure 1), with 
a median of 6·0 (IQR 5·4–6·6, range 2–6) cycles per 
patient. Adverse events and toxicities leading to treatment 
discontinuation were febrile neutropenia (n=1), docu-
mented infections (one patient had infection of the 
surgical wound from lymphoma diagnosis and one had 
persistent cytomegalovirus reactivation), haematological 
toxicity exceeding our previously defi ned criteria (n=9), 
myocardial infarction with cerebral ischaemia (n=1), and 
atrial fi brillation (n=1). The most common haematological 
toxicities requiring discon tinuation were thrombo-
cytopenia (n=3), leucopenia (n=2), or both (n=4). 
Of 57 patients, 41 (72%) had at least one dose reduction 
during the study. 30 patients (53%) delayed the 
subsequent cycle at least once. As specifi ed in the 
protocol, each delay lasted for fewer than 14 days (median 
7 days, IQR 5–9). Overall, 14 (25%) patients received the 
full-dose chemotherapy without dose reduction or delay. 
Granulocyte colony-stimulating factor was given to 
all patients.
Two (4%) patients had disease progression, one after 
the fourth cycle and one after the sixth cycle. Three (5%) 
patients received fewer than four cycles because of 
toxicity and were considered non-responders (fi gure 1). 
All 52 responding patients achieved complete response 
at the end of treatment (complete response 91%, lower 
limit of one-sided 95% CI 85%).
After a median follow-up of 35 months (IQR 30–41, 
range 28–52), 42 (74%) patients were alive and disease 
free. Median progression-free survival was not reached 
(95% CI 42–not reached), nor was median duration of 
response reached (54–not reached). 12 patients died. At 
2 years, overall survival was 86% (74–93), pro gression-
free survival was 81% (68–89), and duration of response 
was 90% (85–94; fi gure 2). Progression-free survival was 
76% (65–85) at median follow-up of 35 months. In post-
hoc subgroup analyses, adverse predictive factors 
aff ecting progression-free survival were high Mantle Cell 
Lymphoma International Prognostic Index (MIPI), 
elevated Ki67 (≥30%), and blastoid morphology (fi gure 3; 
appendix p 2). In multivariate analysis, elevated Ki67 
(hazard ratio 7·43, 95% CI 1·75–31·57; p=0·0062) and 
blastoid variant (4·16, 1·12–18·52; p=0·043) were 
independent predictors of worse progression-free 
survival (appendix p 3). Patients with either of these two 
features had a signifi cantly worse 2 year progression-free 
survival (41%, 19–63) compared with patients with 
classical or pleomorphic variants and low Ki67 (98%, 
84–100; fi gure 3D).
Of 57 patients, 45 (79%) had a molecular marker (29 in 
the immunoglobulin heavy-chain variable region, 
eight had BCL1-based targets, and eight had both). No 
diff erence in clinical or pathological characteristics 
(demographics, Ki67, morphology, or MIPI) was seen 
between patients with a molecular marker and those 
without (appendix p 4). After two cycles of RBAC500, 
24 (54%) patients had molecular response in the bone 
Figure 2: Kaplan-Meier plots
(A) Overall survival. (B) Progression-free survival. (C) Duration of response.
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marrow and 28 (62%) had molecular response in 
peripheral blood; at the end of treatment, 24 (54%) had 
molecular response in the bone marrow and 35 (78%) 
had molecular response in peripheral blood. Of the 
28 patients with available sample 1 year after the end of 
treatment, 16 (57%) had molecular response in the bone 
marrow and 21 (75%) had molecular response in 
peripheral blood. In a post-hoc analysis, no association 
was found between molecular response and progression-
free survival, possibly because of the low number of 
events in this study. A comprehensive report on the 
association between molecular response and outcome, 
together with quantitative PCR fi ndings, will be 
published separately.
The primary toxicity was reversible myelosuppression 
(table 2). Platelet transfusions were administered in 
89 (29%) of 304 delivered cycles. Overall, 23 (40%, 
upper limit of one-sided 95% CI 53%) of 57 patients 
had at least one episode of relevant toxicity. Most 
treatment-related non-haematological adverse events 
and common events were of grade 1–2. Unlike a 
previous study of R-BAC,14 elevation of γ-glutamyl 
transferase was rare with RBAC500. Six (11%) patients 
had grade 3–4 documented infections or viral 
reactivations, and other grade 3–4 non-haematological 
toxicities included infusion-related reactions, fatigue, 
elevated glutamic–pyruvic transaminase and glutamic-
oxaloacetic transaminase, and cardiac events (table 3). 
No renal toxicity or grade 3–4 alopecia was reported. 
Of 41 patients who had dose reduction, 14 (34%) had 
grade 4 cytopenias (20% of cycles).
The 12 deaths reported during the study were attributed 
to disease progression (n=9), cerebral stroke (n=1; 
4 months after end of treatment), sepsis (n=1; 12 months 
after end of treatment), and heart failure (n=1; 39 months 
after end of treatment). No treatment-related deaths were 
recorded. 
Discussion
In this phase 2 trial of 57 treatment-naive elderly patients 
with mantle cell lymphoma, the RBAC500 regimen was 
active and induced PET-negative complete response in 
Figure 3: Subgroup analyses of progression-free survival
(A) MIPI risk category. (B) Ki67 expression. (C) Morphological variants. (D) High Ki67 expression or blastoid variants versus low Ki67 expression and non-blastoid variants. MIPI=Mantle Cell Lymphoma 
International Prognostic Index. 
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91% of patients. Progression-free survival was 81% at 
2 years and 76% at the median follow-up of 35 months, 
without any maintenance therapy. The toxicity of 
RBAC500 was substantially reduced compared with 
results from the pilot trial of the same regimen but higher 
cytarabine dose,14 while effi  cacy was comparable. The 
most common toxicity in our trial was grade 3–4 
thrombocytopenia (52% of cycles). Cytopenias were 
frequent but well managed with dose reduction, and were 
rarely complicated by major infective or haemorrhagic 
issues, making this regimen generally applicable to elderly 
patients (aged 80 years or younger) who are fi t. However, 
RBAC500 was more toxic than historical controls of 
bendamustine–rituximab.5,8
Complete response and median progression-free 
survival in our study compare favourably with 
established fi rst-line treatments in elderly patients with 
mantle cell lymphoma, including bendamustine–
rituximab and R-CHOP, with or without maintenance. 
Two phase 3 studies5,8 have investigated the role of 
bendamustine–rituximab in the treatment of previously 
untreated patients with mantle cell lymphoma and those 
with other histological subtypes. In the STiL study,5 
median progression-free survival for the subgroup of 
patients with mantle cell lymphoma (median age 
70 years) was 35·4 months (IQR 28·8–54·9). In the 
BRIGHT study,8 complete response based on PET 
assessment was achieved in 17 (50%) of 34 patients with 
mantle cell lymphoma, but data for progression-free 
survival were not available. In 2016, the Nordic 
Lymphoma Group assessed the addition of lenalidomide 
to bendamustine–rituximab in 51 patients with similar 
characteristics as in our study population.21 32 (64%) 
patients achieved complete remission, and median 
progression-free survival (42 months, 95% CI 31–53) 
was better than that expected with bendamustine–
rituximab alone. However, grade 3–5 infections were 
reported in 21 (42%) patients, and second primary 
malignancies in eight (16%) patients. Finally, another 
phase 2 study22 assessed 23 transplantation-eligible 
patients treated upfront with alternating bendamustine–
rituximab and rituximab–cytarabine. Although most 
(21 [91%]) patients had low-risk or intermediate-risk 
MIPI and no patient had the blastoid variant, the 
proportion of patients achieving complete response after 
six treatment cycles (96% [22 patients]) and progression-
free survival at 13 month follow-up (96%, 90% CI 73–99) 
were similar to data in this trial and our previous study.14 
This trial used the same drugs as in our trial, although 
in a diff erent schedule, and had similar results to this 
study and our previous trial,14 thus confi rming the 
synergism between these drugs.
In the European MCL Network’s trial,6 485 patients with 
similar age (median 70 years, range 60–87) and risk 
(242 [50%] with high-risk MIPI) to our cohort were 
randomly assigned to receive R-CHOP or R-FC (rituximab, 
fl udarabine, and cyclophosphamide), and responders 
were randomised again to receive main tenance therapy 
with rituximab or interferon alfa. 81 (34%) of 239 patients 
receiving R-CHOP achieved complete response, with a 
median time to treatment failure of 28 months. Compared 
with R-CHOP, the VR-CAP regimen, which replaces 
vincristine in R-CHOP with bortezomib, improved the 
quality of response (complete response 42% vs 53%) and 
signifi cantly prolonged median progression-free survival 
(14·4 months vs 24·7 months).7 In the ECOG’s phase 2 
study,23 75 previously untreated patients with mantle cell 
lymphoma were given VcR-CVAD (rituximab, bortez-
omib, modifi ed hyper-cyclophosphamide, doxorubicin, 
vin cristine, and dexa methasone) induction chemotherapy. 
Of the 44 patients (of whom nine [22%] had high-risk 
MIPI) who were ineligible for autologous stem-cell 
transplantation and were given rituximab maintenance 
instead, 31 (70%) achieved complete response with VcR-
CVAD, and 3 year progression-free survival from the start 
of rituximab maintenance was 67% (95% CI 52–85). 
In another phase 2 study,24 R-CHOP plus bortezomib, 
followed by bortezomib maintenance, led to a 2 year 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 0 91 (30%) 79 (26%) 52 (17%) 82 (27%)
Neutropenia 0 46 (15%) 109 (36%) 43 (14%) 106 (35%)
Febrile neutropenia ¨ ¨ ¨ 12 (4%) 3 (1%)
Thrombocytopenia 0 43 (14%) 103 (34%) 49 (16%) 109 (36%)
Anaemia 63 (21%) 73 (24%) 131 (43%) 36 (12%) 1 (<1%)
Data are n (%). 304 cycles were given in total. 
Table 2: Treatment cycles with haematological toxicities
All grades Grade 1–2 Grade 3 Grade 4
Nausea or vomiting 12 (21%) 12 (21%) 0 0
Stomatitis 3 (5%) 3 (5%) 0 0
Infusion-related reactions 
or tumour lysis syndrome
12 (21%) 11 (19%) 1 (2%) 0
Constipation or diarrhoea 6 (11%) 6 (11%) 0 0
Fatigue 14 (25%) 13 (23%) 1 (2%) NA
Documented infections 9 (16%) 3 (5%) 4* (7%) 2† (4%)
Elevation of 
glutamic-pyruvic 
transaminase and 
glutamic-oxaloacetic 
transaminase or 
γ-glutamyl transferase
6 (11%) 5 (9%) 1 (2%) 0
Alopecia 3 (5%) 3 (5%) 0 0
Rash or desquamation 5 (9%) 5 (9%) 0 0
Cardiac events 3 (5%) 0 2‡ (4%) 1§ (2%)
Data are n (%). NA=not applicable. *One patient had Herpes zoster reactivation, two 
had cytomegalovirus reactivation, and one had fungal infection. 
†Pseudomonas aeruginosa and Staphylococcus aureus sepsis in the course of grade 3–4 
neutropenia. ‡One symptomatic atrial fi brillation and one chest pain without 
sequelae. §Myocardial infarction with cerebral ischaemia during P aeruginosa sepsis. 
Table 3: Non-haematological toxicity occurring in at least one patient
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progression-free survival of 62% (95% CI 49–72) and a 
median progression-free survival of 29·5 months.
Consistent with results from the literature,9–11,14,24,25 Ki67 
expression was the strongest predictive marker of 
progression-free survival, overall survival, and duration 
of response in our study. Patients with low Ki67 (<30%) 
had a long-term progression-free survival of around 90% 
without maintenance therapy. The two patients with 
progressive disease both had elevated Ki67 (≥30%). Ki67 
expression has also been reported to be a strong 
predictive marker of treatment response and outcome 
after intensive or targeted therapies, such as the 
combination of ibrutinib and rituximab.25–27 Future 
studies should stratify patients on the basis of this 
easy-to-assess variable, and newer therapeutic options for 
patients with elevated Ki67 are urgently needed.
In our study, most assessed patients did not have 
minimal residual disease (assessed by nested PCR) in the 
bone marrow and peripheral blood at the end of 
treatment. The proportion of patients with molecular 
response in peripheral blood at the end of treatment 
(79%) was higher in our study than that assessed by real-
time quantitative PCR after R-CHOP (48%)—but similar 
to R-FC (80%) or RiBVD (rituximab, bendamustine, 
bortezomib, and dexamethasone; 83%)—in elderly 
patients with mantle cell lymphoma.28,29 In a trial of 
lenalidomide plus bendamustine–rituximab using nested 
PCR,21 molecular response (19 [56%] of 32 patients in 
bone marrow) was similar to that in our study.
Regarding the statistical design of this trial, our study 
had divergent results with respect to the targets of the 
primary endpoints: the proportion of patients achieving 
complete response was higher than expected and toxicity 
was higher than expected. These discordant results suggest 
that the overall type I error (ie, erroneously rejecting the 
null hypotheses) should not have been infl ated under the 
assumption of independence between response and 
toxicity, even considering that deviations from this 
assumption have generally little eff ect on the Bryant and 
Day design.19 In our trial, toxicity was substantial but 
manageable. Overall, 23 patients had at least one episode 
of relevant toxicity, which exceeded our initial assumption 
(<18 of 57). Haematological toxicity, especially grade 4 
thrombo cytopenia (36% of cycles), was frequent but 
reduced compared with results from a previous trial of 
R-BAC (64% of cycles).14 Grade 3–4 thrombocytopenia and 
neutropenia were reported in 70% and 74% of patients, 
respectively. Dose reduction was required in most 
(72%) patients and was associated with reduced grade 4 
cytopenias (20% of cycles). These frequencies are higher 
than those reported for R-CHOP (162 [67%] of 242 patients 
had grade 3 or higher thromocytopenia and 14 [6%] had 
grade 3 or higher neutropenia),7 but similar to those 
reported for induction regimens including bortezomib.7,23 
Indeed, toxicities reported during VcR-CVAD or VR-CAP 
were mainly haematological, with grade 3–4 thrombo-
cytopenia occurring in 67% of patients given VcR-CVAD 
and 57% of those given VR-CAP, and grade 3–4 neutropenia 
occurring in 84% of those given VcR-CVAD and 85% of 
those given VR-CAP. By contrast, bendamustine–
rituximab has much lower frequency of grade 3–4 
cytopenias than in the present study.5,8 In our study, non-
haematological toxicity was uncommon, and grade 3–4 
alopecia was not observed.
In the past 2 years, new therapies have shown noticeable 
activity in previously untreated patients with mantle cell 
lymphoma. In a trial reported in 2015,30 patients with 
mantle cell lymphoma treated upfront with prolonged 
administration of lenalidomide and rituximab (n=38) had 
high complete response (64%, 95% CI 46–79), with a 
2 year progression-free survival of 85% (67–94). In this 
study, one-third of patients had low-risk MIPI, no patient 
had the pleomorphic or blastoid variant, and Ki67 index 
was low in 26 patients (76% of those with available data). 
These drugs off er new chemotherapy-free opportunities 
for treatment of mantle cell lymphoma and should be 
tested in tumours with elevated Ki67, in which 
chemoimmuno therapy does not off er long-term benefi t.
In conclusion, our results support the use of RBAC500 
in elderly patients with mantle cell lymphoma. Despite 
exceeding our prespecifi ed toxicity criteria, this regimen 
led to high complete response, with a low frequency of 
severe or life-threatening adverse events. Haematological 
toxicity was frequent but manageable with dose 
reduction and supportive care. Responses were durable 
without the use of maintenance therapy and compared 
favourably with previously reported regimens, including 
bendamustine–rituximab, in this patient population. 
With several new expensive drugs on the market, 
RBAC500 is a regimen that is worth studying in a 
phase 3 trial. Further studies are needed to confi rm our 
fi ndings.
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